Selected Publications
Tang F, Ng CM, Horn J, Bada HS, Leggas M. Pharmacokinetic Modeling and Model-Based Hypothesis Generation for Dose Optimization of Clonidine in Neonates With Neonatal Opioid Withdrawal Syndrome. Clin Pharmacol Ther 2025 May;117(5):1254-1263. doi: 10.1002/cpt.3507. Epub 2024 Nov 22. PMID: 39575611; PMCID: PMC11993295.
Bada HS, Westgate PM, Sithisarn T, Yolton K, Charnigo R, Pourcyrous M, Tang F, Gibson J, Shearer-Miller J, Giannone P, Leggas M. Clonidine as Monotherapy for Neonatal Opioid Withdrawal Syndrome: A Randomized Trial. Pediatrics 2024 Nov 1;154(5):e2023065610. doi: 10.1542/peds.2023-065610. PMID: 39403061; PMCID: PMC11524040.
Maillard M, Nishii R, Yang W, Hoshitsuki K, Chepyala D, Lee SHR, Nguyen JQ, Relling MV, Crews KR, Leggas M, Singh M, Suang JLY, Yeoh AEJ, Jeha S, Inaba H, Pui CH, Karol SE, Trehan A, Bhatia P, Antillon Klussmann FG, Bhojwani D, Haidar CE, Yang JJ. Additive effects of TPMT and NUDT15 on thiopurine toxicity in children with acute lymphoblastic leukemia across multiethnic populations. J Natl Cancer Inst 2024 May 8;116(5):702-710. doi: 10.1093/jnci/djae004. PMID: 38230823; PMCID: PMC11077315.
Miller JS, Bada HS, Westgate PM, Sithisarn T, Leggas M. Neonatal Abstinence Signs during Treatment: Trajectory, Resurgence and Heterogeneity. Children (Basel) 2024 Feb 5;11(2):203. doi: 10.3390/children11020203. PMID: 38397314; PMCID: PMC10887053.
Miller JS, Bada HS, Leggas M, Westgate PM. Assessment of the relative clinical utility of shortened Finnegan neonatal abstinence scoring tools. J Perinatol 2022 Aug;42(8):1051-1057. doi: 10.1038/s41372-022-01419-0. Epub 2022 Jun 3. PMID: 35660789.
Rivas JR, Liu Y, Alhakeem SS, Eckenrode JM, Marti F, Collard JP, Zhang Y, Shaaban KA, Muthusamy N, Hildebrandt GC, Fleischman RA, Chen L, Thorson JS, Leggas M, Bondada S. Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia. Leukemia 2021. DOI: 10.1038/s41375-021-01217-1
Tang F, Ng CM, Bada HS, Leggas M. Clinical pharmacology and dosing regimen optimization of neonatal opioid withdrawal syndrome treatments. Clin Transl Sci 14(4):1231-1249, 2021. DOI: 10.1111/cts.12994. PMC8301571
Hedrick SL, Luo D, Kaska S, Niloy KK, Jackson K, Sarma R, Horn J, Baynard C, Leggas M, Butelman ER, Kreek MJ, Prisinzano TE. Design, synthesis, and preliminary evaluation of a potential synthetic opioid rescue agent. J Biomed Sci 28(1):62, 2021. DOI: 10.1186/s12929-021-00758-y
Liu Y, Eckenrode JM, Zhang Y, Zhang J, Hayden RC, Kyomuhangi A, Ponomareva LV, Cui Z, Rohr J, Tsodikov OV, Van Lanen SG, Shaaban KA, Leggas M, Thorson JS. Mithramycin 2'-Oximes with Improved Selectivity, Pharmacokinetics, and Ewing Sarcoma Antitumor Efficacy. J Med Chem 63(22):14067-14086, 2020. DOI: 10.1021/acs.jmedchem.0c01526. PMC7810150
Hughes RR, Shaaban KA, Ponomareva LV, Horn J, Zhang C, Zhan CG, Voss SR, Leggas M, Thorson JS. OleD Loki as a Catalyst for Hydroxamate Glycosylation. Chembiochem 21(7):952-957, 2020. DOI: 10.1002/cbic.201900601. PMC7124993
Arnold SM, Chansky K, Baggstrom MQ, Thompson MA, Sanborn RE, Villano JL, Waqar SN, Hamm J, Leggas M, Willis M, Rosales J, Crowley JJ. Phase II Trial of Carfilzomib Plus Irinotecan in Patients with Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy. Clin Lung Cancer 21(4):357-364.e7, 2020 DOI: 10.1016/j.cllc.2020.01.006.
Ye Q, Zhang Y, Cao Y, Wang X, Guo Y, Chen J, Horn J, Ponomareva LV, Chaiswing L, Shaaban KA, Wei Q, Anderson BD, St Clair DK, Zhu H, Leggas M, Thorson JS, She QB. Frenolicin B Targets Peroxiredoxin 1 and Glutaredoxin 3 to Trigger ROS/4E-BP1-Mediated Antitumor Effects. Cell Chem Biol 26(3):366-377.e12, 2019. DOI: 10.1016/j.chembiol.2018.11.013. PMC6557261
Tang F, Tsakalozou E, Arnold SM, Ng CM, Leggas M. Population pharmacokinetic analysis of AR-67, a lactone stable camptothecin analogue, in cancer patients with solid tumors. Invest New Drugs 37(6):1218-1230, 2019. DOI: 10.1007/s10637-019-00744-0. PMC6713628
Tang F, Bada H, Ng CM, Leggas M. Validation of a HPLC/MS method for simultaneous quantification of clonidine, morphine and its metabolites in human plasma. Biomed Chromatogr 33(7):e4527, 2019. DOI: 10.1002/bmc.4527. PMC6559858
Liu X, Adane E, Tang F, Leggas M. Pharmacokinetic modeling of the blood-stable camptothecin analog AR-67 in two different formulations. Biopharm Drug Dispos 40(8):265-275, 2019. DOI: 10.1002/bdd.2199.
Lee NR, Zheng G, Leggas M, Janganati V, Nickell JR, Crooks PA, Bardo MT, Dwoskin LP. GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine. J Pharmacol 371(2):526-543, 2019. DOI: 10.1124/jpet.119.258699. PMC6863457
Hayden RC, Leggas M. Novel Drug Treatments for Ewing Sarcoma. Current Molecular Biology Reports. Molecular Biology Reports 5(4):153-166, 2019.
Eckenrode JM, Mitra P, Rohr J, Leggas M. Bioanalytical method for quantitative determination of mithramycin analogs in mouse plasma by HPLC-QTOF. Biomed Chromatogr 33(8):e4544, 2019. DOI: 10.1002/bmc.4544.
Mitra P, Eckenrode JM, Mandal A, Jha AK, Salem SM, Leggas M, Rohr J. Development of Mithramycin Analogues with Increased Selectivity toward ETS Transcription Factor Expressing Cancers. J Med Chem 61(17):8001-8016, 2018. DOI: 10.1021/acs.jmedchem.8b01107. PMC6888919
El-Refai SM, Brown JD, Arnold SM, Black EP, Leggas M, Talbert JC. Epidemiologic Analysis Along the Mevalonate Pathway Reveals Improved Cancer Survival in Patients Who Receive Statins Alone and in Combination with Bisphosphonates. JCO Clin Cancer Inform 1:1-12, 2017. DOI: 10.1200/cci.17.00010. PMC6467073
Arnold SM, Chansky K, Leggas M, Thompson MA, Villano JL, Hamm J, Sanborn RE, Weiss GJ, Chatta G, Baggstrom MQ. Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553). Invest New Drugs 35(5):608-615, 2017. DOI: 10.1007/s10637-017-0441-4. PMC5577369
Bada HS, Sithisarn T, Gibson J, Garlitz K, Caldwell R, Capilouto G, Li Y, Leggas M, Breheny P. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics 135(2):e383-91, 2015. DOI: 10.1542/peds.2014-2377
Tsakalozou E, Adane ED, Liang Y, Arnold SM, Leggas M. Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans. Cancer Chemother Pharmacol 74(1):45-54, 2014. DOI: 10.1007/s00280-014-2472-2
Tsakalozou E, Adane ED, Kuo KL, Daily A, Moscow JA, Leggas M. The effect of breast cancer resistance protein, multidrug resistant protein 1, and organic anion-transporting polypeptide 1B3 on the antitumor efficacy of the lipophilic camptothecin 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67) in vitro. Drug Metab Dispos 41(7):1404-1413, 2013. DOI: 10.1124/dmd.112.050021. PMC3684821
Last update: April 2025